Fundraising Fox
/Companies
Sign in

Deep Genomics

Toronto, CA · Founded 2014 · 112 employees on LinkedIn · 9 known investors

Find your way into Deep Genomics

Each arrow is one introduction. Sign up to fill in the first one.

2,504 people can intro you to Brendan

Ask Nessan Bermingham to introduce you to Brendan Frey

You →Nessan · together at Deep Genomics →Brendan

637 people can intro you to Tom

Ask Jamie Chen to introduce you to Tom Masterson

You →Jamie · together at Idea Couture Inc. →Tom

395 people can intro you to Brian

Ask Sam Okafor to introduce you to Brian O'Callaghan

You →Sam · together at Bolt Biotherapeutics →Brian

Sign up to find every way you can get introduced to Deep Genomics

  • Your email: who you already know at Deep Genomics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Deep Genomics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Deep Genomics develops AI-based biological foundation models to identify drug targets and design molecules, aiming to speed up drug discovery. Its platform combines lab-in-the-loop workflows, training datasets, and screening technologies to find candidates for developing new medicines.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

Deep Genomics was founded in 2014 by Brendan Frey.

BFBrendan Frey
Brendan FreyFounderBrendan Frey founded Deep Genomics in 2015 to develop machine learning approaches for genetic medicine and drug discovery. He is a professor of engineering and medicine at the University of Toronto and has authored over 200 peer-reviewed papers on machine learning and genomics, including contributions to Nature, Science, and Cell.
BOBrian O'Callaghan
Brian O'CallaghanChief Executive OfficerBrian O'Callaghan is CEO of Deep Genomics and brings over 30 years of life sciences experience, including senior management and board roles at biotech, pharmaceutical, and contract research organizations across North America and Europe. His background spans public and private companies at various development stages, with expertise in business development, M&A, fundraising, and operational leadership.
DJDavid Johnston
David JohnstonChief Financial OfficerHe has held senior financial leadership roles at ImmunoGen, Aveo Oncology, and Genzyme Biosurgery, where he oversaw public offerings and strategic financing initiatives, and holds degrees from Washington and Lee University and the University of Michigan.
CBClive Bertram
Clive BertramChief Business OfficerHe has held commercial and business development roles across pharmaceutical, biotech, and medical device companies, with experience in product lifecycle management, licensing, and M&A transactions.
TMTom Masterson
Tom MastersonChief Operating OfficerHe previously worked in medical devices, contract research, and healthcare strategy, and founded Caregiver Support Technologies, a digital platform for family caregivers. He holds a B.Sc. in Cell Biology and Genetics from the University of British Columbia and an M.B.A. from Harvard Business School.
GHGreg Hoffman
Greg HoffmanChief Scientific OfficerA biophysicist and cell biologist, he has spent over 10 years in the biotech industry leading teams on genomic screening, small molecule discovery, synthetic biology, and cell and gene therapy development.

Investors · 9

Bloomberg Betalisted by Bloomberg BetaSan Francisco · $25K – $1M

How we know: the VCSheet dataset · github.com · open dataset · 5k.vc investor directory · Not right? Tell us

Future Ventureslisted by Future VenturesLos Altos · $1M – $10M

How we know: Future Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Kensington Capital Partners Limitedlisted by Kensington Capital Partners LimitedToronto
Magnetic Ventureslisted by Magnetic VenturesBoston · $1M – $6M

How we know: Magnetic Ventures's portfolio page · Not right? Tell us

SoftBank Vision Fundlisted by SoftBank Vision FundLondon
True Ventureslisted by True VenturesSan Francisco · $500K – $3Mvia Adam D'Augelli · led

How we know: True Ventures's portfolio page · a partner's Signal profile · Not right? Tell us

Creative Destruction Lab (CDL)reportedToronto · $50K – $250K

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

NJF CapitalreportedLondon

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Founder mafia

The Deep Genomics mafia →

6 people who came through Deep Genomics went on to found or lead other companies.

Nessan BerminghamBoard MemberFounded Korro Bio +2Paul SekhriMember Board of DirectorsFounded VtvtherapeuticsPhilip FradkinComputational BiologistFounded Blank BioDorsa RohaniMachine Learning InternFounded MosaicBrian O'CallaghanChief Executive OfficerFounded Acucela Inc.Thong Q. LeMember Board of DirectorsFounded Automera

Related companies · 4

OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
Genomics PlcGenomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers. It serves life sciences companies and healthcare systems through its Life Sciences and Health & Wellness divisions.
10X Genomics10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.
IDbyDNAScalable, high throughput DNA sequencing platforms.

Companies working in the same space as Deep Genomics.

Frequently asked questions

What does Deep Genomics do?
Deep Genomics develops AI-based biological foundation models to identify drug targets and design molecules, aiming to speed up drug discovery. Its platform combines lab-in-the-loop workflows, training datasets, and screening technologies to find candidates for developing new medicines.
Who founded Deep Genomics?
Deep Genomics was founded by Brendan Frey in 2014.
Who are Deep Genomics's investors?
Deep Genomics's investors include 11.2 Capital, Bloomberg Beta, Future Ventures, Kensington Capital Partners Limited, Magnetic Ventures, SoftBank Vision Fund, True Ventures, Creative Destruction Lab (CDL) and 1 more.
Where is Deep Genomics headquartered?
Deep Genomics is headquartered in Toronto, CA.